Physician

Internal Medicine

Dr. Metin Kurtoglu, MD

Metin Kurtoglu practices Internal Medicine. Metin Kurtoglu, MD is a published doctor and has 24 publications published. The lastest was: 'Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.'

Publications

Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.
The wonders of 2-deoxy-d-glucose.
Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.
Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells.
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits kaposi's sarcoma-associated herpesvirus replication and gene expression.
Serosurveillance study on transmission of H5N1 virus during a 2006 avian influenza epidemic.
Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the...
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
Antiangiogenic activity of 2-deoxy-D-glucose.
A novel functional CT contrast agent for molecular imaging of cancer.
2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.
AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging.
High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors.
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia ...
Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation.
Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells.
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.
Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".
[Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)].

Doctors Specialties

Medical Oncology
Oncology
Internal Medicine

Accepted Insurances

Education

National Institutes of Health Clinical Center
Jackson Memorial Hospital - Jackson Health System
Istanbul University Faculty of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Timothy M. Quast, MD This Doctor is OpenDoctor Recommended.
	Barbara Martinez This Doctor is OpenDoctor Recommended.
	Dr. Vanya D. Wagler, DO
	Dr. Cicely A. Dye, MD
	Dr. Neil S. Otchin, MD This Doctor is OpenDoctor Recommended.
	Dr. Melissa S. Butts, DO